Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut R Mäcke

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|March 30, 2006
Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PETAntonia Dimitrakopoulou-Strauss, Vassilios Georgoulias, Michael Eisenhut, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2015
Towards tailored radiopeptide therapyPiotr Radojewski, Rebecca Dumont, Nicolas Marincek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analogJochen Schuhmacher, Hanwen Zhang, Josef Doll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trialFabienne Iten, Beat Müller, Christian Schindler, et al.
Nuclear Medicine and Biology|March 12, 2004
Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneysMartin Kopecky, Vladimir Semecky, Frantisek Trejtnar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2010
Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CTDamian Wild, Andreas Wicki, Rosalba Mansi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2005
CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogsBerthold A Nock, Theodosia Maina, Martin Béhé, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2003
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I studyLisa Bodei, Marta Cremonesi, Stefania Zoboli, et al.
International Journal of Cancer|April 12, 2002
Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor modelSylvie Froidevaux, Alex N Eberle, Martine Christe, et al.
EJNMMI Research|February 18, 2014
Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumorsAndreas Wicki, Damian Wild, Vincent Prêtre, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
European Journal of Nuclear Medicine and Molecular Imaging|March 30, 2006
Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PETAntonia Dimitrakopoulou-Strauss, Vassilios Georgoulias, Michael Eisenhut, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2015
Towards tailored radiopeptide therapyPiotr Radojewski, Rebecca Dumont, Nicolas Marincek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analogJochen Schuhmacher, Hanwen Zhang, Josef Doll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trialFabienne Iten, Beat Müller, Christian Schindler, et al.
Nuclear Medicine and Biology|March 12, 2004
Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneysMartin Kopecky, Vladimir Semecky, Frantisek Trejtnar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2010
Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CTDamian Wild, Andreas Wicki, Rosalba Mansi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2005
CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogsBerthold A Nock, Theodosia Maina, Martin Béhé, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2003
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I studyLisa Bodei, Marta Cremonesi, Stefania Zoboli, et al.
International Journal of Cancer|April 12, 2002
Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor modelSylvie Froidevaux, Alex N Eberle, Martine Christe, et al.
EJNMMI Research|February 18, 2014
Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumorsAndreas Wicki, Damian Wild, Vincent Prêtre, et al.
Pageof 3